Inhibrx, Inc. (INBX)

20,53 -1,21 (-5,57%) Börsenschluss: 04:00PM EDT

Inhibrx, Inc.

11025 North Torrey Pines Road
Suite 200 Torrey Pines Science Park
La Jolla, CA 92037
United States
858 795 4220
https://inhibrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 132

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mark Paul Lappe	Founder, Chairman, Pres & CEO	994,28k	N/A	1967
Dr. Brendan P. Eckelman Ph.D.	Founder & Chief Scientific Officer	644,5k	N/A	1979
Ms. Kelly Devine Deck B.S., CPA, M.S.	Exec. VP & CFO	423,75k	N/A	1981
Mr. Quinn L. Deveraux	Founder	N/A	N/A	N/A
Dr. Ashraf Amanullah	Exec. VP & Chief Technical Operations Officer	N/A	N/A	1968
Ms. Leah Pollema J.D.	VP, Corp. Sec. & Gen. Counsel	N/A	N/A	N/A
Dr. Charbel Helaihel Pharm.D.	VP of Marketing & Commercial Planning	N/A	N/A	N/A
Mr. Jeffrey J. Jensen	EVP & Chief Clinical Devel. Officer	N/A	N/A	N/A
Mr. David Matly M.B.A.	Exec. VP & Chief Commercial Officer	N/A	N/A	N/A
Dr. Carlos Bais Ph.D.	Exec. VP of Translational Sciences	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

Corporate Governance

Inhibrx, Inc.s ISS Governance QualityScore, Stand 1. März 2023, lautet 9. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.